UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006713
Receipt number R000007928
Scientific Title Chronotherapy for oral squamous cell carcinoma -Attempt to reduce side-effects associated with DCF chemotherapy-
Date of disclosure of the study information 2011/11/12
Last modified on 2021/03/08 12:36:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Chronotherapy for oral squamous cell carcinoma -Attempt to reduce side-effects associated with DCF chemotherapy-

Acronym

Chronotherapy of DCF chemotherapy

Scientific Title

Chronotherapy for oral squamous cell carcinoma -Attempt to reduce side-effects associated with DCF chemotherapy-

Scientific Title:Acronym

Chronotherapy of DCF chemotherapy

Region

Japan


Condition

Condition

oral squamous cell carcinoma

Classification by specialty

Oral surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To clarify whether the adverse effects associated with the docetaxel/cisplatin/5-fluorouracil were reduced by changing dosing-time of day.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Incidence of Grade 3 or higher neutropenia

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

1. Normal Regimen group: Dosing with docetaxel and cisplatin at morning

Interventions/Control_2

2. Chronotherapy regimen group: Dosing with docetaxel and cisplatin at evening

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Stage III, IV an oral squamous cell carcinoma
2. General condition (ECOG Performance Status) is 0-2
3. Satisfy the following criteria within 14 days before registration:
# Leukocyte: 3,000/mm3 <=
# Neutrophil: 2,000/mm3 <=
# Hemoglobin: 10g/dL <=
# Platelet: 100,000/mm3 <=
# AST and ALT: =< 100
# Total Bilirubin: =< 1.5 mg/dL
# Creatinine clearance: 60ml/min <=

Key exclusion criteria

1. Severe hypersensitivity to study drugs
2. With active bacterial and fungal infections
3. Have serious complications (such as chronic obstructive pulmonary disease, pulmonary fibrosis, angina requiring treatment, heart failure)
4. Severe diarrhea
5. Pregnant women or who have a hope of pregnancy
6. Doctor judged unsuitable for participating in this study

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Tadahide
Middle name
Last name Noguchi

Organization

Jichi Medical University

Division name

Department of Oral & Maxillofacial Surgery

Zip code

329-0498

Address

3311-1 Yakushiji, Shimotsuke, Tochigi

TEL

0285-58-7390

Email

tadahide.noguchi@gmail.com


Public contact

Name of contact person

1st name Tadahide
Middle name
Last name Noguchi

Organization

Jichi Medical University

Division name

Department of Oral & Maxillofacial Surgery

Zip code

329-0498

Address

3311-1 Yakushiji, Shimotsuke, Tochigi

TEL

0285-58-7390

Homepage URL


Email

tadahide.noguchi@gmail.com


Sponsor or person

Institute

Department of Oral & Maxillofacial Surgery, Jichi Medical University

Institute

Department

Personal name



Funding Source

Organization

Japan Research Foundation For Clinical Pharmacology

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Research Ethics Review Committee, Jichi Medical University

Address

3311-1 Yakushiji, Shimotsuke, Tochigi

Tel

0285-58-8933

Email

rinri@jichi.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 11 Month 12 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

9

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 10 Month 05 Day

Date of IRB

2011 Year 10 Month 05 Day

Anticipated trial start date

2011 Year 11 Month 01 Day

Last follow-up date

2016 Year 03 Month 31 Day

Date of closure to data entry

2016 Year 03 Month 31 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 11 Month 12 Day

Last modified on

2021 Year 03 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007928


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name